Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (clinicaltrials.gov) - Sep 15, 2026 - P3 | N=233 | Terminated | Sponsor: Immunovant Sciences GmbH | Trial completion date: Feb 2027 ➔ Aug 2026 | Active, not recruiting ➔ Terminated; Sponsor Decision
Trial completion date • Trial termination • CNS Disorders • Immunology • Myasthenia Gravis
|